The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
During the 52nd week since the first coronavirus case appeared in the United States, the U.S. surpassed 24.6 million total cases and 410,100 deaths due to the pandemic. Here’s our recap of the past week in the coronavirus pandemic from our tracking, policy analysis, polling, and journalism.
A new Policy Watch, Early State Vaccination Data Raise Warning Flags for Racial Equity, explores the latest state-reported data on vaccination by race/ethnicity available on KFF’s COVID-19 state data and policy tracker.
Across states, data to understand access to and uptake of the vaccine by race/ethnicity and other demographic factors will be central to efforts to ensure equity. KFF is compiling and will regularly update state-reported data on vaccination by race/ethnicity through its COVID-19 state data and policy tracker.
This analysis provides an overview of demographic characteristics and health insurance coverage of health care workers with direct patient contact, including those working in hospital and long-term care settings.
Republicans and Black Americans are More Likely to Be Hesitant but Even Among These Groups Reasons Vary KFF has launched a new COVID-19 Vaccine Monitor to dive deeply into the public’s views about the vaccine and experiences getting it for as long as the pandemic lasts.
This initial survey for the KFF COVID-19 Vaccine Monitor tracks the public’s attitudes and experiences with COVID-19 vaccinations, with a focus on sub-groups of Americans. It explores confidence in vaccines, assesses trust in messengers, and highlights key challenges for vaccination efforts.
As the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also requires two doses, to shed light on this potential challenge of the leading COVID-19 vaccine candidates.
Approaching the end of 2020, two of the most pressing concerns facing the country are the long-standing issue of racial discrimination and the ongoing coronavirus pandemic. The issues have merged with the pandemic taking a disproportionate health and economic toll on people of color.
This brief provides an overview of barriers to vaccination that disproportionately affect people of color and discusses how current national recommendations and state vaccine allocation plans address racial equity.
New coronavirus cases in the United States have hit daily records multiple times in the past week and hospitalizations are rising in several areas of the country.
© 2025 KFF